Mark J. Holterman, Medical

About PAPS Membership

 

Pacific Association of Pediatric Surgeons pic
Pacific Association of Pediatric Surgeons
Image: pacificassociationofpediatricsurgeons.org

A longtime proponent of stem cell research and therapy, Mark Holterman, MD, serves as pediatrics professor at the University of Illinois College of Medicine in Peoria. Alongside his work, Dr. Mark Holterman belongs to the Pacific Association of Pediatric Surgeons (PAPS).

PAPS is an exclusive organization aimed at promoting fellowship and education among doctors who are from Pacific Rim nations. The organization currently has more than 500 members spanning 23 countries. Surgeons who spend more than 90 percent of their time in pediatric care are eligible to join the organization through geography and by invitation.

Potential applicants must either currently be practicing pediatric surgery in a Pacific-bordering country. If that surgeon moves away from the Pacific area, they can remain in the organizations by attending at least three PAPS meetings within the last decade. They must also be practicing pediatric surgeons for at least a year before becoming eligible to apply for membership.

Advertisements
Mark J. Holterman, Medical

American Diabetes Association Issues Joint Guidance on CGMs

 

American Diabetes Association pic
American Diabetes Association
Image: diabetes.org

Possessing decades of experience as both a physician and an educator, Mark Holterman, MD, serves as a professor of medicine at the University of Illinois College of Medicine. In addition to his work educating students, Dr. Mark Holterman is a longtime supporter of the American Diabetes Association.

Continuous glucose monitoring (CGM) systems provide people with diabetes real-time feedback about changes in their blood sugar levels. This helps them decide whether or not to eat different things or integrate some exercise into their daily routines. Even though these devices offer significant benefits to patients, they are not used as much as they could be, because a lack of standardized guidelines exist on how they should be prescribed. That’s why the American Diabetes Association has partnered with the European Association for the Study of Diabetes to issue a joint statement called “Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations.”

The new statement provides recommendations on marketing, clinical data reporting, and regulatory guidance, among other items. It can be found in the December 2017 edition of Diabetes Care and is based on a comprehensive examination of 50-plus scientific articles about CGMs.

Mark J. Holterman, Medical

The Potential of Regenerative Medicine to Restore Organ Function

 

Dr. Mark J. Holterman pic
Dr. Mark J. Holterman
Image: osfhealthcare.org

Dr. Mark Holterman, a longtime advocate of regenerative medicine and stem cell therapy, serves as pediatrics professor at the University of Illinois College of Medicine in Peoria. Reflecting decades of research employing ethically sourced fetal stem cells, Mark J. Holterman, MD, seeks to promote the academic study of the safety and efficacy of innovative treatment modalities.

An emerging area of medical science, regenerative medicine at its foundation centers on restoring the functionality of organs and tissues, specifically those that have been damaged or are associated with chronic disease and severe injuries that do not respond to conventional therapies. Restoration of function is enabled through a combination of tissue engineering and gene editing advancements, which allows stem cells to be remodeled as three-dimensional tissue structures and organoids that meet highly specific needs.

Enabling this is the potentially limitless ability of stem cells to divide and transdifferentiate into a variety of cell types. As such, stem cells provide a foundation for the body’s full range of organs and tissues. Employing microengineering and cell transplantation techniques, organoids are grown that have the potential to take the place of donated organs and tissues, which are of limited supply and expensive.

Mark J. Holterman, Medical

Three Patient Benefits of Cellular Therapies

 

Mark J Holterman
Mark J Holterman

A pediatric surgeon with more than two decades of experience, Mark Holterman, MD, teaches medical students and residents at the University of Illinois College of Medicine and serves as the chief medical officer for Mariam Global Health. Dr. Mark Holterman also maintains an interest in stem cell therapy and has published numerous articles on the subject. Stem cell therapies offer multiple benefits to patients, as outlined below.

1. Treats a wide range of conditions. From cardiovascular and neurodegenerative diseases to orthopedic injuries, cellular therapies can treat a broad spectrum of medical conditions. Research indicates that cellular therapies can help stimulate the repair and growth of blood vessel tissues surrounding the heart and offer relief from degenerative symptoms associated with neurodegenerative diseases. Medical researchers also suspect that adult stem cells may possess the ability to help patients with autoimmune diseases and diabetes.

2. Promotes wound healing. Stem cell therapy accelerates tissue growth and boosts the body’s production of collagen, a protein found in skin, muscles, bones, blood vessels, and the digestive system that strengthens skin and replaces dead cells. The increase of collagen concentration tightens damaged tissue and reduces scars by growing healthy tissue.

3. Improved success for transplants. Cellular therapies give patients the option to transplant cells from one area of their body to another, which decreases the possibility of a rejection response.

Mark J. Holterman, Medical

Cellular Therapy FAQs

 

Alliance for the Advancement of Cellular Therapies pic
Alliance for the Advancement of Cellular Therapies
Image: aact.co

Mark Holterman, MD, PhD, teaches surgery and pediatrics at the University of Illinois College of Medicine. As a cofounder of the Alliance for the Advancement of Cellular Therapies (AACT), Dr. Mark Holterman promotes the safe and ethical advancement of regenerative medicine and stem-cell therapies. The following addresses some frequently asked questions about cellular therapies.

Q: What are cellular therapies?

A: Cellular therapy (CT) entails transplanting human cells to enhance the body’s ability to fight disease and restore tissue and cells. When the body is injured, its adult stem cells activate, traveling to the site of the injury and giving signals to start the healing process. With age, the number of these cells decreases. However, with CT, stem cells are taken from bone marrow or fat and implanted at the injured or diseased site when there is an inadequate supply.

Q: For what diseases can cellular therapies be used?

A: Some diseases that cellular therapies may be used for are osteoarthritis and joint pain, autoimmune disorders, alopecia, and psoriasis.

Q: Are cellular therapies ethical?

A: There are no ethical issues involved in adult stem-cell therapy since they are not embryonic stem cells.

Mark J. Holterman, Medical

IPSAC-VN International Scholar Program

 

IPSAC-VN pic
IPSAC-VN
Image: ipsacvietnam.org

As a professor of surgery and pediatrics at the University of Illinois College of Medicine, Mark Holterman, MD, PhD, conducts medical research and teaches medical students and surgical residents. Dr. Mark Holterman also supports the International Pediatric Specialists Alliance for the Children of Vietnam (IPSAC-VN).

IPSAC-VN endeavors to improve the care of children in Vietnam by enhancing health care, using education and training to increase workforce and institutional capacity, supporting academics, contributing material and equipment, and providing surgery in the remote highlands. The IPSAC-VN International Scholar Program helps to accomplish this objective by awarding $2,500 to licensed and in-training medical personnel for educational expenses, travel, and room and board while spending up to two months being educated in the United States. This education involves observing clinical practices or receiving training in transnational research at a medical institution accredited by the Accreditation Council for Graduate Medical Education (ACGME).

The program is tailored to each chosen scholar who has the goal of enhancing the quality of health care at his or her institution in Vietnam. At the end of the program, all scholars prepare a presentation that details the practices they will carry out to improve patient care.

Mark J. Holterman, Medical

CellR4 – Journal for Cellular Therapies

 

CellR4pic
CellR4
Image: CellR4.org

A pediatrics and surgical professor at the University of Illinois College of Medicine, Mark Holterman, MD, holds board positions with multiple medical organizations. Dr. Mark Holterman also is a cofounder of the Alliance for the Advancement of Cellular Therapies (AACT) and serves on its executive board. The AACT collaborates with the CellR4 medical journal to publish research presented at AACT conferences.

The official journal of the Cure Alliance, CellR4 focuses on studies and medical knowledge regarding cellular repair, regeneration, reprogramming, and differentiation. The journal facilitates discussion on challenges and opportunities involved in developing new treatments. Published content includes information on fundamental new discoveries in basic science and the delivery of innovative therapies to transitional and clinical trials. Additionally, CellR4 shares information on global collaborative efforts and features commentaries and opinion papers on legal, ethical, and regulatory issues.

CellR4’s articles are available for full download at no charge on its website.